Taysha Gene Therapies (TSHA)
5.60
+0.03 (0.54%)
Upcoming Events
Latest Headlines
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 4, 2026 8:00 AM - StreetInsider
Form SCHEDULE 13G/A Taysha Gene Therapies, Filed by: RA CAPITAL MANAGEMENT, L.P.
August 14, 2026 4:50 PM - SEC Filing
Form SCHEDULE 13G/A Taysha Gene Therapies, Filed by: MORGAN STANLEY
August 13, 2026 5:38 PM - SEC Filing
Taysha Gene Therapies (TSHA) Misses Q2 EPS by 1c
August 11, 2026 4:19 PM - StreetInsider
Form 10-Q Taysha Gene Therapies, For: Jun 30
August 11, 2026 4:08 PM - SEC Filing
Form 8-K Taysha Gene Therapies, For: Aug 11
August 11, 2026 4:06 PM - SEC Filing
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 11, 2026 4:00 PM - StreetInsider
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 7, 2026 8:00 AM - StreetInsider
Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11
August 4, 2026 4:00 PM - StreetInsider
Taysha and Catalent sign commercial manufacturing deal for Rett therapy
August 3, 2026 8:00 AM - StreetInsider
Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
August 3, 2026 8:00 AM - StreetInsider
Taysha Gene Therapies (TSHA) PT Raised to $13 at Goldman Sachs
July 21, 2026 6:38 AM - StreetInsider
Form 4 Taysha Gene Therapies, For: Jul 10 Filed by: Nagendran Sukumar
July 10, 2026 6:55 PM - SEC Filing
Form 144 Taysha Gene Therapies, Filed by: Nagendran Sukumar
July 10, 2026 4:22 PM - SEC Filing
Taysha Gene Therapies (TSHA) Reiterated at Market Outperform by Citizens
July 2, 2026 4:19 AM - StreetInsider
Taysha Gene Therapies (TSHA) PT Raised to $15 at Baird
June 29, 2026 1:53 PM - StreetInsider
Form 8-K Taysha Gene Therapies, For: Jun 24
June 25, 2026 4:26 PM - SEC Filing
Form 424B5 Taysha Gene Therapies,
June 25, 2026 4:24 PM - SEC Filing
Taysha Gene Therapies to present TSHA-102 data at 2026 Rett meeting
June 25, 2026 4:01 PM - StreetInsider
Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting
June 25, 2026 4:01 PM - StreetInsider
Taysha Gene Therapies prices $200M public stock offering
June 24, 2026 10:33 PM - StreetInsider
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
June 24, 2026 10:33 PM - Globe NewsWire
Form 424B5 Taysha Gene Therapies,
June 24, 2026 5:21 PM - SEC Filing
Taysha Gene Therapies launches $200M stock and warrant offering
June 24, 2026 4:01 PM - StreetInsider
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
June 24, 2026 4:01 PM - StreetInsider
Taysha Gene Therapies (TSHA) PT Raised to $14 at BMO Capital on Differentiation
June 23, 2026 7:00 AM - StreetInsider
Taysha Gene Therapies (TSHA) PT Raised to $11 at Citizens on REVEAL Data Update
June 23, 2026 4:40 AM - StreetInsider
Taysha Gene Therapies (TSHA) PT Raised to $10 at BofA Securities
June 22, 2026 12:27 PM - StreetInsider
Form 8-K Taysha Gene Therapies, For: Jun 22
June 22, 2026 8:15 AM - SEC Filing
Taysha completes dosing in Rett syndrome pivotal trial, reports data
June 22, 2026 8:00 AM - StreetInsider
Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
June 22, 2026 8:00 AM - StreetInsider
Full Article List
